Boosting mitochondrial supercomplex assembly imp

US President says agreements with more drugmaker

Liom boasts miniaturization breakthrough in spec

Anavex is pushing for a second look at a potenti

A pilot clinical trial led by researchers at Ceda

Humacyte announced the publication of long-term c

Biosplice Therapeutics said the first patient has

An end-of-year experiment exploring how large la

Devin Partida on the fine line between longevity

Startup targets ‘brainspan’ with EEG-powered

A new MRM Health R&D partnership in immunotherap

A lipidomics analysis of young Chinese women fin

NorthStrive Biosciences, a subsidiary of PMGC Hol

“ProMIS Neurosciences announced that its PRECIS

Annovis Bio said it will begin an open-label exte

MUVON Therapeutics announced that Dr Christine Günther, MD, PhD, has been appointed Chief Technology Officer (CTO), effective December 1, 2025, as the clinical-stage biotech advances its regenerative medicine platform for skeletal muscle tissue repair. The company said her addition will strengthen its leadership team and support the next phase of technology development. Dr Günther brings over 30 years of experience in cell and gene therapy development, clinical translation, manufacturing and regulatory affairs, combining scientific innovation with operational leadership in the biotech sector. Her professional background includes more than a decade as CEO and Medical Director of Munich-based apceth (now part of Minaris Regenerative Medicine), where she scaled cell therapy programmes and steered the organisation through growth and acquisition. She previously served as Medical Director at the Bavarian Stem Cell and Cord Blood Bank and held leadership roles in European clinical-stage development and cell-manufacturing organisations. In her new role at MUVON, Dr Günther will oversee the company’s technology strategy, including science, manufacturing and clinical translation, to accelerate its tissue-engineered therapies toward patients. MUVON’s platform focuses on personalised regenerative approaches, with initial programmes such as an autologous muscle precursor cell-based therapy targeting stress urinary incontinence in women. The appointment aligns with MUVON’s…

Telomir Pharmaceuticals said that its lead therap

Life Time has opened a new adults-only fitness an

Regenerative medicine firm says new capital give

FDA clears ENV-308 for Phase 1 as Enveda doses f

Funding accelerates clinical rollout of glycan b

From insulin to GLP-1s, peptide therapies harnes

Urolithin A may support healthier immune aging.

PeptiDream and Alnylam Pharmaceuticals announced

Alnylam Pharmaceuticals said it will invest about

Beacon Biosignals said it has formed a collabor

The fastest-growing supplements of 2025 reveal w

Fountain Life, a health and longevity brand focus

A new industry commentary suggests that the cell

Kenai Therapeutics said it has dosed the first pa

The global blood glucose monitor market is foreca

Prof David Allison on healthspan, nutrition and

Zealand Pharma partners Shanghai-based OTR Thera

Survey finds C-suite sentiment improving, dealma

UK and Singapore link regulators to help patient

Rona Therapeutics announced the submission of its

4D Molecular Therapeutics announced positive inte

Targeted nutrient transport is gaining traction

OpenAI-backed Chai Discovery lands $130m, claimi

With new investor backing, the company prepares

Sun Pharma can manufacture and export, but the D

Beacon Therapeutics announced that it has dosed t

Texas A&M study shows small, consistent physical

Aviceda Therapeutics announced topline results fr

Longevity experts say you don’t need supplemen

New health platform converts labs, wearables and

Initial focus on epilepsy could drive progress i

Phase III trial shows up to 28.

AB Science announced the publication of a new pre

Serina Therapeutics announced the appointment of